SMO and cancer: We further evaluated the survival differences between the SMO_MUT and SMO_WT groups in two non-ICI-treated pan-cancer cohorts to explore whether the OS advantage can be attributed to ICI treatment in patients carrying SMO mutations or was just simply due to its general prognostic impact.